Jubilant Pharmova Ltd (JUBLPHARMA) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Jubilant Pharmova faces a critical Q1 FY27 as it balances significant currency tailwinds against ongoing operational headwinds in its high-margin Radiopharma segment. Investors will be looking for clarity on the pace of SPECT product supply normalization and the progress of the Montreal CDMO facility's remediation following recent regulatory scrutiny.

Jubilant Pharmova Ltd Q1 Results Date and Time

The company has scheduled a board meeting on August 07, 2026, to consider the unaudited financial results for the quarter ended June 30, 2026.

What to expect from Jubilant Pharmova Ltd's Q1 FY27 results

Jubilant Pharmova enters Q1 FY27 with a mixed outlook as the company navigates a temporary SPECT supply shortage that management quantified as a $14 million revenue impact for H1 FY27. While the ~8–9% year-on-year INR depreciation provides a mechanical tailwind for its 94% USD-denominated revenue, the margin profile remains pressured by the ongoing under-absorption of costs at the Montreal facility, which reported an EBITDA loss of ~Rs. 150 Cr in FY26. Management has explicitly framed FY27 as a two-half story, targeting H2 EBITDA margins in the 17%–18% range as the Montreal site stabilizes and SPECT supply normalizes. The upcoming call will likely focus on whether the Q1 revenue trajectory aligns with the company's vision of doubling group revenue to Rs. 13,500 Cr by FY30, supported by the ramp-up of Spokane Line 3 and continued share gains in the US allergy market.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring progress against FY27 and long-term strategic targets.

• Radiopharma low double-digit growth target for FY27 — Q1 run-rate
• Group H2 FY27 EBITDA margin target of 17–18% — Q1 as baseline
• SPECT supply shortage impact — quantify actual Q1 revenue hit against $14M H1 guidance
• CDMO Line 3 revenue target of $60–$80 million for FY27 — Q1 contribution

Montreal Facility Remediation: Tracking operational recovery following the FDA Warning Letter.

• Status of CAPA implementation and customer re-qualification milestones
• Montreal EBITDA loss reduction pace in Q1 versus FY26 baseline of ~Rs. 150 Cr
• Any update on customer retention or new order pipeline impact

Spokane Operational Status: Updates on CDMO capacity and regulatory compliance.

• Response status to 8 observations from the June 17, 2026, FDA inspection
• RFP traction and commercial production ramp for Line 3
• Progress on PET radiopharmacy network expansion ($50M investment)

Generics and CRDMO Growth: Tracking margin expansion and segment-specific momentum.

• Generics EBITDA margin progression toward the 15% target
• CRDMO demand outlook and FTE capacity buildout toward 4,000 target
• Performance of branded India business relative to 1.5x industry average growth